This is a clean win for Amgen — the court invalidated the certifications and barred recertification on the same basis, removing a known channel of 340B diversion. The ruling is immediately enforceable (no stay mentioned) and unlikely to be reversed on appeal given the government's own concession that HRSA should not certify subgrantees. Monitor for any appeal filing by the government or intervenor Community Care Resources of Florida, and for potential follow-on suits against other Sagebrush-affiliated clinics.
Price Chart
Executive Summary
Amgen and other drug manufacturers won summary judgment in D.D.C. against HHS, invalidating HRSA's certification of 11 clinics as 340B covered entities. The court found the clinics received funding through private intermediary Sagebrush, not directly from a state or local government as required by statute, and ordered their certifications set aside. This ruling removes a mechanism that had generated over $30 million in discounts to the clinics between 2022-2025, reducing 340B program leakage for Amgen and co-plaintiffs.
Court Ruling Details
Key Facts
- Amgen, Eli Lilly, UCB, and Genentech won summary judgment on their central claim that 11 clinics were impermissibly certified as 340B covered entities.
- The court held that the clinics received qualifying STD funding through private entity Sagebrush, not through a state or local government as 42 U.S.C. § 256b(a)(4)(K) requires.
- The clinics had received over $30 million in 340B discounts between 2022 and 2025.
- The court ordered that the clinics' present and prior certifications be set aside and that HHS not recertify them based on funds received through Sagebrush or another private entity.
- The ruling applies to 11 clinics — 8 currently certified in Nevada and 3 previously certified in Connecticut.
- Judge James E. Boasberg issued the memorandum opinion on August 14, 2026.
Financial Impact
The 11 clinics received over $30 million in 340B discounts from 2022-2025; decertification eliminates future leakage of that magnitude for Amgen and co-plaintiffs.
Risk Factors
- Government or intervenor may appeal the ruling to the D.C. Circuit, though the government's own litigation position conceded the core legal principle.
- The ruling is limited to the 11 specific clinics and the Sagebrush structure; it does not set broader precedent on 340B certification of other entity types.
- Remaining claims for declaratory relief on other legal theories were dismissed without prejudice and could be refiled.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-8d2682a987-AMGN |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | ANALYST-DOWNGRADE | $382.47 $379.78 | ▲ +0.70% | ▲ +0.20% | $403.04 (−5.38%) |
Sep 8, 2026 24d ago | ANALYST-DOWNGRADE | $393.17 $375.65 | ▲ +4.46% | ▲ +3.34% | $403.04 (−2.51%) |
Aug 14, 2026 7w ago | Court Ruling | $415.21 $439.33 | ▲ +5.81% | ▲ +7.18% | $403.04 (−2.93%) |
Aug 13, 2026 7w ago | Insider Cluster | $415.21 $439.33 | ▲ +5.81% | ▲ +7.18% | $403.04 (−2.93%) |
Aug 11, 2026 7w ago | Court Ruling | $414.30 $425.28 | ▲ +2.65% | ▲ +3.05% | $403.04 (−2.72%) |
Aug 7, 2026 7w ago | Insider Cluster | $417.20 $419.38 | ▲ +0.52% | ▲ +0.57% | $403.04 (−3.39%) |
Aug 7, 2026 7w ago | Insider Cluster | $417.20 $419.38 | ▲ +0.52% | ▲ +0.57% | $403.04 (−3.39%) |
Aug 7, 2026 7w ago | Insider Cluster | $417.20 $419.38 | ▲ +0.52% | ▲ +0.57% | $403.04 (−3.39%) |
Aug 4, 2026 8w ago | GOVT-CONTRACT | $390.02 $414.30 | ▲ +6.23% | ▲ +6.33% | $403.04 (+3.34%) |
Jul 31, 2026 9w ago | 8-K | $378.87 $417.20 | ▼ −10.12% | ▼ −8.09% | $403.04 (−6.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access